Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
ADVAIR DISKUS 100/50 |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid + long-acting β2-agonist. |
| Generic Name |
|
Fluticasone propionate 100 micrograms, salmeterol (as xinafoate) 50 micrograms; per inh; dry pwd for inh. |
| Also |
• ADVAIR DISKUS 250/50
• ADVAIR DISKUS 500/50
|
| Indications |
|
Maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications or whose disease severity warrants initiation of 2 maintenance therapies. |
| Children |
|
<4yrs: not recommended. Allow approximately 12 hours between doses. Asthma: 4–11yrs: 1 inh of 100/50 twice daily. Rinse mouth after use. |
| Adults |
|
Allow approximately 12 hours between doses. Asthma: ≥12yrs: not previously on inhaled steroid: 1 inh of 100/50 or 250/50 twice daily; already on inhaled steroid: see literature. If insufficient response after 2 weeks, use next higher strength. Max 1 inh of 500/50 twice daily. COPD: 1 inh of 250/50 twice daily. Rinse mouth after use. |
| Contraindications |
|
Not for treatment of acute attacks or intensive measures of COPD. Concomitant with other forms of salmeterol or formoterol. Severe milk protein sensitivity. |
| Precautions |
|
Reevaluate periodically. Do not exceed recommended dose. Not for use with other long-acting β2-agonists or for transferring from systemic steroids. Do not initiate in significantly worsening or acutely deteriorating asthma. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Hyperthyroidism. Convulsive disorders. Hepatic impairment. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Immunosuppressed. If exposed to chicken pox or measles, consider immune globulin prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Monitor potassium, intraocular pressure; bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occurs, discontinue gradually). Do not use with spacers. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
See Contraindications. Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, ritonavir): not recommended. Caution with other sympathomimetics (except short-acting bronchodilators), during or within 2 weeks of MAOIs, tricyclic antidepressants (increased cardiac effects), K+–depleting diuretics. Antagonized by β-blockers. |
| Adverse Reactions |
|
Upper respiratory tract infection or inflammation, pneumonia, laryngeal spasm or swelling, headache, dizziness, hoarseness, dysphonia, sinusitis, pain, GI upset, candidiasis, cough, paradoxical bronchospasm, musculoskeletal pain; rarely: serious asthma episode, asthma-related death. Children: also epistaxis. |
| How Supplied |
|
Diskus (60 blisters)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
